Solid Biosciences Inc (SLDB) Stock Price, Quote & News

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 337 4680

Website: www.solidbio.com

Address:

500 Rutherford Avenue, Third Floor, Charlestown, United States

rsm14il Jun. 25 at 4:57 PM

$SLDB 3 more items: Cash position is strong HCW recently reiterated buy and $20 PT 8 million shares short

0 · Reply

1VincentVega Jun. 25 at 4:53 PM

$SLDB seems we’re getting some love from people getting out of $SRPT

1 · Reply

rsm14il Jun. 25 at 3:56 PM

$SLDB a sleeper; additional interim data on Duchenne before FDA meeting could send it over $9

0 · Reply

pharmd2828 Jun. 25 at 1:16 PM

$SLDB https://www.barrons.com/articles/pfizer-stock-dmd-fda-sarepta-5ce45c42 Good for SLDB imho

1 · Reply

Michael1965now Jun. 25 at 9:57 AM

$SLDB Price action, and Short Interest. Predicts a combination of a short squeeze.

1 · Reply

pharmd2828 Jun. 25 at 8:12 AM

$SLDB wildly is buy buy ! MACD indicates buy too! IMHO do your DD!

1 · Reply

GammaRadiated Jun. 24 at 7:51 PM

$SLDB looking for that over 5.00 level before it sky rockets

1 · Reply

Thekiss320 Jun. 24 at 12:45 PM

$SLDB

0 · Reply

flexdiggs Jun. 23 at 9:59 PM

$SLDB ho hum,.fake shake out before another run

0 · Reply

GammaRadiated Jun. 23 at 6:08 PM

$SLDB Taking a punch in the face today!!!

0 · Reply

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 8:00 AM EDT - 4 weeks ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 15, 2025, 4:06 PM EDT - 5 weeks ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 8, 2025, 4:50 PM EDT - 2 months ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Mar 31, 2025, 2:25 PM EDT - 3 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Mar 12, 2025, 8:00 AM EDT - 3 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 6, 2025, 4:16 PM EST - 3 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 8:00 AM EST - 4 months ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Feb 18, 2025, 12:29 PM EST - 4 months ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 7:00 AM EST - 4 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 6:45 AM EST - 4 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Jan 21, 2025, 6:27 PM EST - 5 months ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 8:30 AM EST - 5 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 15, 2025, 4:05 PM EST - 5 months ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 8, 2025, 4:05 PM EST - 6 months ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:15 PM EST - 6 months ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Dec 23, 2024, 4:05 PM EST - 6 months ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 13, 2024, 1:52 PM EST - 6 months ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Nov 14, 2024, 8:00 AM EST - 7 months ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 6, 2024, 4:05 PM EST - 8 months ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 8:00 AM EDT - 10 months ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:08 PM EDT - 11 months ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 1, 2024, 4:19 PM EDT - 1 year ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Mar 13, 2024, 7:44 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Jan 16, 2024, 11:01 PM EST - 1 year ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 8, 2024, 7:09 AM EST - 1 year ago

Solid Biosciences Announces $109 Million Private Placement

Nov 22, 2023, 8:00 AM EST - 1 year ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 4:17 PM EST - 1 year ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Aug 14, 2023, 4:17 PM EDT - 2 years ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Jefferies Healthcare Conference

May 22, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

May 16, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

May 11, 2023, 7:30 AM EDT - 2 years ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

May 8, 2023, 4:05 PM EDT - 2 years ago

Solid Biosciences to Present at JMP Securities Life Sciences Conference

Apr 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Mar 7, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at Barclays Global Healthcare Conference

Feb 8, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

Jan 26, 2023, 8:00 AM EST - 2 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA's Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

Jan 11, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Jan 9, 2023, 4:26 PM EST - 2 years ago

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

rsm14il Jun. 25 at 4:57 PM

$SLDB 3 more items: Cash position is strong HCW recently reiterated buy and $20 PT 8 million shares short

0 · Reply

1VincentVega Jun. 25 at 4:53 PM

$SLDB seems we’re getting some love from people getting out of $SRPT

1 · Reply

rsm14il Jun. 25 at 3:56 PM

$SLDB a sleeper; additional interim data on Duchenne before FDA meeting could send it over $9

0 · Reply

pharmd2828 Jun. 25 at 1:16 PM

$SLDB https://www.barrons.com/articles/pfizer-stock-dmd-fda-sarepta-5ce45c42 Good for SLDB imho

1 · Reply

Michael1965now Jun. 25 at 9:57 AM

$SLDB Price action, and Short Interest. Predicts a combination of a short squeeze.

1 · Reply

pharmd2828 Jun. 25 at 8:12 AM

$SLDB wildly is buy buy ! MACD indicates buy too! IMHO do your DD!

1 · Reply

GammaRadiated Jun. 24 at 7:51 PM

$SLDB looking for that over 5.00 level before it sky rockets

1 · Reply

Thekiss320 Jun. 24 at 12:45 PM

$SLDB

0 · Reply

flexdiggs Jun. 23 at 9:59 PM

$SLDB ho hum,.fake shake out before another run

0 · Reply

GammaRadiated Jun. 23 at 6:08 PM

$SLDB Taking a punch in the face today!!!

0 · Reply

pharmd2828 Jun. 23 at 3:51 PM

$SLDB added more!

1 · Reply

NeverPop Jun. 23 at 2:33 PM

$SLDB will It hold the 200 mda?

0 · Reply

Thekiss320 Jun. 23 at 12:57 PM

$SLDB

0 · Reply

Bio_Invest101 Jun. 21 at 2:02 PM

$SLDB SI is second highest in record after R/S and somebody bet big for Monday or next week

2 · Reply

Thekiss320 Jun. 21 at 6:08 AM

$SLDB

0 · Reply

Bangra Jun. 20 at 8:17 PM

$SLDB Did anyone buy or sell a large amount of shares at the end of the day?

2 · Reply

NeverPop Jun. 20 at 4:57 PM

$SLDB SGT-501 CPVT 🧐

0 · Reply

GammaRadiated Jun. 20 at 1:31 PM

$SLDB https://www.marketbeat.com/stock-ideas/sarepta-drops-42-on-fatalities-markets-eye-solid-biosciences/ Getting some positive buzzzzzzzzz!!!!

0 · Reply

Joshbull420 Jun. 20 at 8:58 AM

$SLDB

0 · Reply

GammaRadiated Jun. 19 at 1:42 PM

$SLDB https://www.gurufocus.com/news/2930444/solid-biosciences-sldb-gains-confidence-amid-safety-concerns-with-rival-therapy-sldb-stock-news there we go!!!

3 · Reply

pharmd2828 Jun. 17 at 2:13 PM

$SLDB any pullbacks are healthy & I feel are buying opportunities!! Please do your DD!

0 · Reply

JarvisFlow Jun. 17 at 11:30 AM

HC Wainwright & Co. has updated their rating for Solid Biosciences ( $SLDB ) to Buy with a price target of 20.

0 · Reply

Market Cap	376.34M
Revenue (ttm)	0.00
Net Income (ttm)	-124.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	820,800
Avg Vol	1,730,024
Day's Range	N/A - N/A
Shares Out	77.52M
Stochastic %K	41%
Beta	2.22
Analysts	Strong Sell
Price Target	$16.10